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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Probenecid prevents 
acute tubular necrosis 
in a mouse model 
of aristolochic acid 
nephropathy
Aristolochic acid (AA) causes tubulointer­
stitial nephritis in humans, and experi­
mental AA nephropathy is a commonly 
used rodent model of acute kidney injury 
(AKI) that leads to chronic tubulointersti­
tial inflammation and fibrosis. Baudoux 
and co­workers studied whether treatment 
with probenecid, which blocks organic 
anion transporter (OAT)­mediated 
entry of AA into proximal tubular cells, 
can protect mice from AA nephro pathy. 
Probenecid inhibited AA­induced increase 
in serum creatinine and histopatho­
logic tubu lointerstitial injury. Moreover, 
probenecid reduced AA­induced mito­
chondrial injury and DNA damage as 
assessed by AA–DNA adduct formation 
and immunohistochemistry for prolifer­
ating cell nuclear antigen. This study dem­
onstrates that preventing OAT­mediated 
transport of AA into tubular epithelial cells 
with probenecid prevents renal epithelial 
injury and AKI. See page 1105. 
Treatment with 
tacrolimus and 
prednisolone 
is preferable 
to intravenous 
cyclophosphamide as 
the initial therapy for 
children with steroid-
resistant nephrotic 
syndrome
Clinicians who treat children with steroid­
resistant nephrotic syndrome currently 
choose among potentially toxic therapies, 
including cyclophosphamide and calcineu­
rin inhibitors, based on limited data. In 
this issue, Gulati et al. report the results of 
a multicenter study in which 131 children 
with steroid­resistant nephrotic syndrome 
were randomized to receive tacrolimus for 
12 months or 6 monthly infusions of cyclo­
phosphamide. Tacrolimus induced a higher 
proportion of complete and partial remis­
sion of nephrotic syndrome at 12 months, 
and patients treated with tacrolimus had 
fewer serious adverse events. This study 
provides much­needed high­quality data 
supporting the use of tacrolimus in children 
with steroid­resistant nephrotic syndrome 
and proves that it is possible to perform rig­
orous randomized controlled trials in this 
patient population. See page 1130.
Autosomal dominant 
polycystic kidney 
disease is associated 
with central and 
nephrogenic defects  
in osmoregulation
Autosomal dominant polycystic kid­
ney disease (ADPKD) is associated with 
reduced urinary concentrating capac­
ity, which until now has been attributed 
to inability of cystic kidneys to normally 
respond to arginine vasopressin (AVP). 
Ho and colleagues studied two cohorts of 
adult and pediatric ADPKD patients to 
determine the contribution of impaired 
release of AVP from the brain to impaired 
osmoregulation. In this elegant study, 
they found that adults and children with 
ADPKD had reduced urinary concentrat­
ing capacity that was independent of cyst 
size. Interestingly, they also found that 
ADPKD subjects had lower levels of AVP 
after water deprivation. They further dem­
onstrated that the PKD1 and PKD2 genes 
are expressed in the hypothalamus, sug­
gesting that mutations in these genes may 
impair osmoregulation by reducing hypo­
thalamic AVP secretion. See page 1121.
